{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T22:41:33.807887+00:00","company":{"ticker":"NAUT","cik":1808805,"company_name":"Nautilus Biotechnology, Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"2cce7777df9d9911b93b2db8ebcc55a3a3d2a868","cik":1808805,"ticker":"NAUT","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2026-04-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$14.7 million","period_text":"the quarter ended March 31, 2026","report_date":"2026-04-28","result_type":"reported_results","revenue_text":null},"claim":"Nautilus Biotechnology, Inc. reported the quarter ended March 31, 2026 results: net income $14.7 million.","evidence_excerpt":"Net loss was $14.7 million for the first quarter of 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001808805-26-000015","anchor_url":"https://secwatch.observer/filing/0001808805-26-000015#claim-2cce7777df9d9911b93b2db8ebcc55a3a3d2a868","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/0001808805-26-000015-index.htm"},{"fact_type":"executive_change","fact_key":"75b9655f13","cik":1808805,"ticker":"NAUT","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-02-27T23:59:59+00:00","payload":{"action":"agreed to resign as a Class II director and to stand for election as a Class I director","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Matthew McIlwain departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001808805-25-000004","anchor_url":"https://secwatch.observer/filing/0001808805-25-000004#claim-75b9655f13","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm"},{"fact_type":"executive_change","fact_key":"38fb08b154","cik":1808805,"ticker":"NAUT","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-02-27T23:59:59+00:00","payload":{"action":"will not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Altman departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001808805-25-000004","anchor_url":"https://secwatch.observer/filing/0001808805-25-000004#claim-38fb08b154","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm"},{"fact_type":"executive_change","fact_key":"ed77919d04","cik":1808805,"ticker":"NAUT","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-02-27T23:59:59+00:00","payload":{"action":"will not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Vijay Pande departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001808805-25-000004","anchor_url":"https://secwatch.observer/filing/0001808805-25-000004#claim-ed77919d04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm"},{"fact_type":"executive_change","fact_key":"10537a29e5","cik":1808805,"ticker":"NAUT","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-01-31T23:59:59+00:00","payload":{"action":"informed that they will not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Altman departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001808805-25-000002","anchor_url":"https://secwatch.observer/filing/0001808805-25-000002#claim-10537a29e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/0001808805-25-000002-index.htm"},{"fact_type":"executive_change","fact_key":"935609445b","cik":1808805,"ticker":"NAUT","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-01-31T23:59:59+00:00","payload":{"action":"informed that they will not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Vijay Pande departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001808805-25-000002","anchor_url":"https://secwatch.observer/filing/0001808805-25-000002#claim-935609445b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000002/0001808805-25-000002-index.htm"},{"fact_type":"earnings_release","fact_key":"8fce703af7ae58bced1fb386018c3bbafba4c01c","cik":1808805,"ticker":"NAUT","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$18.7 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-04-30","result_type":"reported_results","revenue_text":null},"claim":"Nautilus Biotechnology, Inc. reported the first quarter ended March 31, 2024 results: net income $18.7 million.","evidence_excerpt":"Net loss was $18.7 million for the first quarter of 2024","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001808805-24-000038","anchor_url":"https://secwatch.observer/filing/0001808805-24-000038#claim-8fce703af7ae58bced1fb386018c3bbafba4c01c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000038/0001808805-24-000038-index.htm"}]}